Possible involvement of hyperlipidemia in increasing risk of colorectal tumor development in human familial adenomatous polyposis

Japanese Journal of Clinical Oncology

Volumn 36, Issue 3, 2006, Pages 166-171

  Mutoh, Michihiro ^a   Akasu, Takayuki ^b   Takahashi, Mami ^a   Niho, Naoko ^a   Yoshida, Teruhiko ^a   Sugimura, Takashi ^a   Wakabayashi, Keiji ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

APC gene; Colorectal cancer; Familial adenomatous polyposis; Hyperlipidemia

Indexed keywords

ALBUMIN; APC PROTEIN; CHOLESTEROL; CHOLINESTERASE; PROTEIN; TRIACYLGLYCEROL;

ADENOMATOUS POLYP; ADULT; AGED; AGING; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COLON CARCINOGENESIS; COLON RESECTION; COLORECTAL CANCER; FAMILIAL COLON POLYPOSIS; FAMILIAL POLYPOSIS; FEMALE; GENE MUTATION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; JAPAN; MALE; PILOT STUDY; PREVALENCE; PROTEIN BLOOD LEVEL; RECTUM POLYP; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL;

ADENOMATOUS POLYPOSIS COLI; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; COLORECTAL NEOPLASMS; FEMALE; GENES, APC; GERM-LINE MUTATION; HUMANS; HYPERLIPIDEMIAS; INTESTINAL POLYPS; MALE; MICE; MIDDLE AGED; PILOT PROJECTS; PREVALENCE; RECTAL NEOPLASMS; RISK; TRIGLYCERIDES;

EID: 33645866760     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi233     Document Type: Article

References (24)

1. Varesco L. Familial adenomatous polyposis: Genetics and epidemiology. Tech Coloproctol 2004;8:s305-8
2. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990;247:322-4.
3. Fodde R, Edelmann W, Yang K, van Leeuwen C, Carlson C, Renault B, et al. A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proc Natl Acad Sci USA 1994;91:8969-73.
4. Oshima M, Oshima H, Kitagawa K, Kobayashi M, Itakura C, Taketo M. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proc Natl Acad Sci USA 1995;92:4482-6.
5. Niho N, Takahashi M, Kitamura T, Shoji Y, Itoh M, Noda T, et al. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res 2003;63:6090-5.
6. Niho N, Takahashi M, Shoji Y, Takeuchi Y, Matsubara S, Sugimura T, et al. Dose-dependent suppression of hyperlipidemia and intestinal polyp formation in Min mice by pioglitazone, a PPAR ligand. Cancer Sci 2003;94:960-4.
7. Niho N, Mutoh M, Takahashi M, Tsutsumi K, Sugimura T, Wakabayashi K. Concurrent suppression of hyperlipidemia and intestinal polyp formation by NO-1886, increasing lipoprotein lipase activity in Min mice. Proc Natl Acad Sci USA 2005;102:2970-4.
8. Hata Y, Mabuchi H, Saito Y, Itakura H, Egusa G, Ito H, et al. Working Committee on JAS Guideline for Diagnosis and Treatment of Hyperlipidemias. Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese adults. J Atheroscler Thromb 2002;9:1-27.
9. Prosser J, Condie A, Wright M, Horn JM, Fantes JA, Wyllie AH, et al. APC mutation analysis by chemical cleavage of mismatch and a protein truncation assay in familial adenomatous polyposis. Br J Cancer 1994;70:841-6.
10. Arai H, Yamamoto A, Matsuzawa Y, Saito Y, Yamada N, Oikawa S, et al. Serum lipid survey and its recent trend in the general Japanese population in 2000. J Atheroscler Thromb 2005;12:98-106.
11. Gurbuz AK, Giardiello FM, Petersen GM, Krush AJ, Offerhaus GJ, Booker SV, et al. Desmoid tumours in familial adenomatous polyposis. Gut 1994;35:377-81.
12. Nugent KP, Spigelman AD, Phillips RK. Life expectancy after colectomy and ileorectal anastomosis for familial adenomatous polyposis. Dis Colon Rectum 1993;36:1059-62.
13. Arvanitis ML, Jagelman DG, Fazio VW, Lavery IC, McGannon E. Mortality in patients with familial adenomatous polyposis. Dis Colon Rectum 1990;33:639-42.
14. Bertario L, Presciuttini S, Sala P, Rossetti C, Pietroiusti M. Causes of death and postsurgical survival in familial adenomatous polyposis: results from the Italian Registry. Italian Registry of Familial Polyposis Writing Committee. Semin Surg Oncol 1994;10:225-34.
15. Iwama T, Tamura K, Morita T, Hirai T, Hasegawa H, Koizumi K, et al. Japanese Society for Cancer of the Colon and Rectum. A clinical overview of familial adenomatous polyposis derived from the database of the Polyposis Registry of Japan. Int J Clin Oncol 2004;9:308-16.
16. Groves C, Lamlum H, Crabtree M, Williamson J, Taylor C, Bass S, et al. Mutation cluster region, association between germline and somatic mutations and genotype-phenotype correlation in upper gastrointestinal familial adenomatous polyposis. Am J Pathol 2002;160:2055-61.
17. Dihlmann S, Gebert J, Siermann A, Herfarth C, von Knebel Doeberitz M. Dominant negative effect ofthe APC1309 mutation: A possible explanation for genotype-phenotype correlations in familial adenomatous polyposis. Cancer Res 1999;59:1857-60.
18. Koishi R, Ando Y, Ono M, Shimamura M, Yasumo H, Fujiwara T, et al. Angptl3 regulates lipid metabolism in mice. Nat Genet 2002;30: 151-7.
19. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-9.
20. Kitamura T, Kawamori T, Uchiya N, Itoh M, Noda T, Matsuura M, et al. Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis. Carcinogenesis 2002;23:1463-6.
21. 1 in colon carcinogenesis. Cancer Res 1999;59:5093-6.
22. 4 in colon carcinogenesis. Cancer Res 2002;62:28-32.
23. Waddell WR, Ganser GF, Cerise EJ. Sulindac for polyposis of the colon. Am J Surg 1989;157:175-9.
24. Sinicrope FA, Half E, Morris JS, Lynch PM, Morrow JD, Levin B, et al. Familial Adenomatous Polyposis Study Group. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. Cancer Epidemiol Biomarkers Prev 2004;13:920-7.